DrugPatentWatch Database Preview

Details for Patent: 7,919,483

Which drugs does patent 7,919,483 protect, and when does it expire?

Patent 7,919,483 protects XIMINO and SOLODYN and is included in two NDAs.

This patent has thirteen patent family members in ten countries.

Summary for Patent: 7,919,483

Title:	Method for the treatment of acne
Abstract:	A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.
Inventor(s):	Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Briscoe, TX), Bhatia; Kuljit (Nesconset, NY), Patel; Bhiku (Chandler, AZ)
Assignee:	Medicis Pharmaceutical Corporation (Scottsdale, AZ)
Application Number:	11/166,817
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form; Delivery;

Drugs Protected by US Patent 7,919,483

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Sun Pharm Inds Ltd	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012		RX	No	No	➤ Sign Up	➤ Sign Up				TREATMENT OF ACNE	➤ Sign Up
Sun Pharm Inds Ltd	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-003	Jul 11, 2012		RX	No	No	➤ Sign Up	➤ Sign Up				TREATMENT OF ACNE	➤ Sign Up
Sun Pharm Inds Ltd	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-005	Jul 11, 2012		RX	No	No	➤ Sign Up	➤ Sign Up				TREATMENT OF ACNE	➤ Sign Up
Medicis	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-001	May 8, 2006		DISCN	Yes	No	➤ Sign Up	➤ Sign Up				TREATMENT OF ACNE	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,919,483

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,790,705	Minocycline oral dosage forms for the treatment of acne	➤ Sign Up
8,252,776	Minocycline oral dosage forms for the treatment of acne	➤ Sign Up
8,268,804	Minocycline oral dosage forms for the treatment of acne	➤ Sign Up
7,541,347	Minocycline oral dosage forms for the treatment of acne	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Patents Family Members for US Patent 7,919,483

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006262428	➤ Sign Up
Canada	2613273	➤ Sign Up
China	101208097	➤ Sign Up
European Patent Office	1898925	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,919,483

For more information try a trial or see the plans and pricing